No description available.

Abdul Haq was the secretary of the Anjuman Taraqqi-e-Urdu from 1912 to 1961. He was also a founder of Osmania University, one of the first universities in India to provide instruction in an Indian vernacular. He had a lifelong devotion towards improving the status of Urdu and of the Indian Muslim community at large. He was the figure most involved with the standardization of Urdu and establishment of this language as a symbol of Muslim identity. Through an analysis of Abdul Haq’s involvement in language reform movements and the politics of the early 20th century, especially considering the fallout after the 1936 meeting of the Bharatiya Sahitya Parishad, I seek to show the nature of language as a nationalist tool. I argue that language is not inherently associated with the nation-building process, but that it must first be standardized into a form which can be used as a political tool and a point of identification for the community rallied behind it. / text

Made available in DSpace on 2017-07-21T14:35:55Z (GMT). No. of bitstreams: 1 CAROLYN DE GEUS WENCESLAU.pdf: 1200941 bytes, checksum: 94de972e28ecf64328f568ac13958cef (MD5) Previous issue date: 2016-08-15 / In recent years, Patient Related Outcomes (PROs) have received more importance by providing meaningful informations answered by the patients about their symptoms, functional status, quality of life and satisfaction, and also for giving relevant information about treatment efficacy. The main objective of this study was to evaluate the satisfaction of fibromyalgia patients through PASS and determine the correlation of scores obtained with FIQR in relation to PASS. Other objectives were:to determine the value of best accuracy of FIQR in relation to PASS; to compare the FIQR scores between satisfied and dissatisfied patients and FIQR scores between patients with disability claims or on work disability, in relation to the rest of the sample; to compare the mean scores from HAQ, Beck and PSD questionnaires between satisfied and not satisfied patients and evaluate the correlation between the questionnaires. In the studied sample, 82 fibromyalgia patients were assessed, from public and private healthcare services, according to the modified ACR 2010 criteria. Sociodemographic and clinical data were collected and the impact of fibromyalgia was assessed by FIQR, the satisfaction by PASS and Likert scale, functional capacity by HAQ, depression by the Beck Depression Inventory and the polysymptomatic distress by PSD. In this sample depression (87%) and rheumatological diseases (64%) were the main comorbidities. Most patientes made use of antidepressants (96%) and analgesics (81%), but only 21% of patients performed at least 150 minutes of aerobic exercise per week. The results from the questionnaires showed severe impact of fibromyalgia, severe polysymptomatic distress, moderate to severe functional disability and moderate to severe depression symptoms. Patients with disability claims, or on work disability showed statistical difference in FIQR and Beck mean scores when compared to the rest of the sample. Patient satisfaction was considerably low in PASS (15% satisfied), as well as in Likert scale: 2.3 ± 2.8. There was no statistical difference between sociodemographic and clinical variables in relation to PASS satisfaction, except in older patients (p = 0.03) and patients with longer time since disease diagnosis (p = 0.003), who showed higher satisfaction. Correlation between FIQR and PASS was weak and negative (r = -0.26), showing that alterations in FIQR are little related to patient satisfaction. There was statistical difference (p = 0.001) in FIQR scores between the satisfied and the not satisfied group, and also in scores from other questionnaires comparing both groups, showing that dissatisfied patients have lower quality of life. Strong correlation was demonstrated between FIQR and HAQ questionnaires (r = 0.68) and FIQR and Beck (r = 0.61). The value of best accuracy of FIQR in relation to PASS was 65 (ROC curve), but with low sensitivity and specificity. The best specificity values, which reflect values where 100% of patients are satisfied, were very low for each questionnaire. This sample showed low satisfaction, severe physical and psychological symptoms in fibromyalgia patients, suggesting reinforcement of non pharmacological strategies for the treatment of the disease. And that in studies addressing therapeutic measures for fibromyalgia, satisfaction measures should be used. / Nos últimos anos os PROs: Patient Related Outcomes tem apresentado maior importância por fornecerem informações importantes respondidas pelo próprio paciente em relação aos seus sintomas, estado funcional, qualidade de vida e satisfação, além de permitir avaliar a resposta do paciente ao tratamento instituído. O objetivo principal deste estudo foi avaliar a satisfação dos pacientes com fibromialgia através do PASS e determinar a correlação dos escores obtidos através do FIQR com o PASS. Objetivos específicos foram determinar o valor de melhor acurácia do FIQR em relação ao PASS, comparar as médias dos escores do FIQR,entre pacientes satisfeitos e não satisfeitos e os escores do FIQR entre pacientes afastados do trabalho ou em litígio trabalhista, comparados com o restante da amostra. Também comparar as médias dos escores dos questionários: HAQ, Beck e PSD entre pacientes satisfeitos e não satisfeitos e fazer a correlação entre os questionários. Na amostra estudada foram avaliados 82 pacientes com fibromialgia, provenientes de rede pública e privada, de acordo com os critérios do ACR 2010 modificados. Foram coletados dados sociodemográficos e clínicos, foi avaliado o impacto da fibromialgia através do FIQR, a satisfação pelo PASS e escala de Likert, a capacidade funcional pelo HAQ, a depressão através do Inventário de Depressão de Beck e o estresse polissintomático pelo PSD. Nesta amostra depressão (87%) e doenças reumatológicas (64%) eram as comorbidades mais frequentes. A maioria dos pacientes (96%) fazia uso de antidepressivos e 81% utilizavam analgésicos;mas somente 21% dos pacientes realizavam pelo menos 150 minutos de exercício aeróbico por semana O resultado dos questionários demonstrou um impacto importante da fibromialgia, estresse polissintomático severo, incapacidade funcional moderada a grave e sintomas depressivos de intensidade moderada a grave.Pacientes em litígio trabalhista e aqueles afastados do trabalho demonstraram diferença estatística entre as médias do FIQR e do Beck comparado com o restante da amostra. A satisfação dos pacientes foi bastante reduzida, tanto pelo PASS (15% satisfeitos), quanto pela escala de Likert: 2,3 ± 2,8. Não houve diferença estatística entre as variáveis sociodemográficas e clínicas em relação à satisfação avaliada pelo PASS, exceto em pacientes mais velhos (p = 0,03) e pacientes com maior tempo de diagnóstico da doença (p = 0,003), os quais apresentaram maior satisfação. A correlação entre o FIQR e o PASS foi fraca e negativa (r= -0,26), demonstrando que as alterações no FIQR estão pouco relacionadas com a satisfação do paciente. Houve diferença estatística (p = 0,001) nos escores do FIQR entre o grupo satisfeito e o não satisfeito, e também nos escores dos outros questionários comparando os dois grupos, demonstrando que pacientes insatisfeitos apresentaram menor qualidade de vida. Foi demonstrada correlação forte entre os questionários FIQR e HAQ (r = 0,68) e FIQR e Beck (r = 0,61). O valor de melhor acurácia do FIQR em relação ao PASS foi 65 (curva ROC) mas com sensibilidade e especificidade baixos. Os valores de melhor especificidade, valores onde 100% dos pacientes se encontram satisfeitos, foram bastante baixos para cada questionário analisado. Esta amostra demonstrou pouca satisfação nos pacientes com fibromialgia, impacto importante da doença, associado com severidade de sintomas físicos e psíquicos, sugerindo que no tratamento sejam enfatizadas medidas não farmacológicas e que também, nos estudos que abordam medidas terapêuticas para a fibromialgia, sejam utilizadas medidas de satisfação.

INTRODUÇÃO: Diversos ensaios clínicos randomizados (ECR) foram realizados nos últimos anos sobre a eficácia dos agentes biológicos no tratamento da artrite reumatóide (AR). Porém, as revisões sistemáticas sobre o tema ainda geram dúvidas sobre a real eficácia relacionada à capacidade funcional e qualidade de vida. MÉTODOS: O presente estudo sintetizou as evidências geradas pelas revisões sistemáticas que compararam o tratamento realizado com a utilização dos agentes biológicos e o tratamento convencional com a utilização das drogas anti-reumáticas modificadoras da doença de síntese química (DARMDq), considerando a capacidade funcional e qualidade de vida dos pacientes com AR, além de avaliar a qualidade metodológica das revisões sistemáticas recuperadas. Utilizamos as bases de dados PubMed (Medline), EMBASE e Cochrane para realizar o levantamento de revisões sistemáticas com ou sem meta-análises de ECR. Dois pesquisadores de maneira independente realizaram a seleção das revisões sistemáticas, avaliaram a qualidade metodológica utilizando a ferramenta AMSTAR e classificaram a qualidade das evidências pelo GRADE. RESULTADOS: Esta overview incluiu 10 revisões sistemáticas e meta-análises de ECR que avaliaram a capacidade funcional mensurada pelo HAQ e a qualidade de vida mensurada pelo SF-36 (PCF e PCM) em pacientes com AR que utilizaram a terapia com os agentes biológicos comparada a terapia convencional com a utilização das DARMDq. A maioria da revisões sistemáticas apresentaram alta qualidade metodológica avaliada pela ferramenta AMSTAR e a qualidade da evidência variou entre baixa a alta qualidade pelo GRADE. A melhora da capacidade funcional e qualidade de vida observada no período inicial do tratamento (24 semanas) com a terapia biológica, foi de pequena relevância clínica. Esta diferença entre os tratamentos não foi observada no longo prazo (52 semanas), principalmente com os agentes biológicos na forma de monoterapia. CONCLUSÃO: Evidências que variam entre baixa a alta qualidade mostraram que os agentes biológicos apresentaram melhora de baixa relevância clínica na capacidade funcional e qualidade de vida no período inicial do tratamento em comparação à terapia convencional com as DARMDq. Entretanto, não há diferenças entre a utilização da terapia biológica e da terapia convencional a longo prazo / INTRODUCTION: Several randomized clinical trials (RCTs) have been conducted in recent years on the efficacy of biological agents in the treatment of rheumatoid arthritis (RA). However, systematic reviews on this topic still raise doubts about the real efficacy related to functional capacity and quality of life. METHODS: This study synthesized the evidence generated by systematic reviews comparing the treatment with biological agents and the conventional treatment with disease-modifying antirheumatic drugs (DMARD), considering the functional capacity and quality of life of patients with RA, also evaluating the methodological quality of the systematic reviews retrieved. PubMed (Medline), EMBASE and Cochrane databases were searched for systematic reviews with or without RCT meta-analyzes. Two researchers independently carried out the selection of systematic reviews, assessed the methodological quality using the AMSTAR tool and classified the quality of the evidence by GRADE. RESULTS: This overview included 10 systematic reviews and meta-analyzes of RCTs that assessed functional capacity measured by HAQ and quality of life measured by SF-36 (PCS and MCS) in RA patients who used therapy with biological agents compared to conventional therapy with DMARDq. Most of the systematic reviews presented high methodological quality evaluated by the AMSTAR tool and the quality of the evidence ranged from low to high quality by GRADE. The improvement in functional capacity and quality of life observed in the initial period of treatment (24 weeks) with biological therapy presented low clinical relevance. This difference between the treatments was not observed in the long term (52 weeks), mainly with the biological agents in the form of monotherapy. CONCLUSION: Evidence that varied between low to high quality demonstrated that biological agents presented improvement with low clinical relevance of the functional capacity and quality of life during the initial period of treatment compared to conventional therapy with DMARDq. However, there are no differences in the long term between the use of biological therapy and conventional therapy

INTRODUÇÃO: Diversos ensaios clínicos randomizados (ECR) foram realizados nos últimos anos sobre a eficácia dos agentes biológicos no tratamento da artrite reumatóide (AR). Porém, as revisões sistemáticas sobre o tema ainda geram dúvidas sobre a real eficácia relacionada à capacidade funcional e qualidade de vida. MÉTODOS: O presente estudo sintetizou as evidências geradas pelas revisões sistemáticas que compararam o tratamento realizado com a utilização dos agentes biológicos e o tratamento convencional com a utilização das drogas anti-reumáticas modificadoras da doença de síntese química (DARMDq), considerando a capacidade funcional e qualidade de vida dos pacientes com AR, além de avaliar a qualidade metodológica das revisões sistemáticas recuperadas. Utilizamos as bases de dados PubMed (Medline), EMBASE e Cochrane para realizar o levantamento de revisões sistemáticas com ou sem meta-análises de ECR. Dois pesquisadores de maneira independente realizaram a seleção das revisões sistemáticas, avaliaram a qualidade metodológica utilizando a ferramenta AMSTAR e classificaram a qualidade das evidências pelo GRADE. RESULTADOS: Esta overview incluiu 10 revisões sistemáticas e meta-análises de ECR que avaliaram a capacidade funcional mensurada pelo HAQ e a qualidade de vida mensurada pelo SF-36 (PCF e PCM) em pacientes com AR que utilizaram a terapia com os agentes biológicos comparada a terapia convencional com a utilização das DARMDq. A maioria da revisões sistemáticas apresentaram alta qualidade metodológica avaliada pela ferramenta AMSTAR e a qualidade da evidência variou entre baixa a alta qualidade pelo GRADE. A melhora da capacidade funcional e qualidade de vida observada no período inicial do tratamento (24 semanas) com a terapia biológica, foi de pequena relevância clínica. Esta diferença entre os tratamentos não foi observada no longo prazo (52 semanas), principalmente com os agentes biológicos na forma de monoterapia. CONCLUSÃO: Evidências que variam entre baixa a alta qualidade mostraram que os agentes biológicos apresentaram melhora de baixa relevância clínica na capacidade funcional e qualidade de vida no período inicial do tratamento em comparação à terapia convencional com as DARMDq. Entretanto, não há diferenças entre a utilização da terapia biológica e da terapia convencional a longo prazo / INTRODUCTION: Several randomized clinical trials (RCTs) have been conducted in recent years on the efficacy of biological agents in the treatment of rheumatoid arthritis (RA). However, systematic reviews on this topic still raise doubts about the real efficacy related to functional capacity and quality of life. METHODS: This study synthesized the evidence generated by systematic reviews comparing the treatment with biological agents and the conventional treatment with disease-modifying antirheumatic drugs (DMARD), considering the functional capacity and quality of life of patients with RA, also evaluating the methodological quality of the systematic reviews retrieved. PubMed (Medline), EMBASE and Cochrane databases were searched for systematic reviews with or without RCT meta-analyzes. Two researchers independently carried out the selection of systematic reviews, assessed the methodological quality using the AMSTAR tool and classified the quality of the evidence by GRADE. RESULTS: This overview included 10 systematic reviews and meta-analyzes of RCTs that assessed functional capacity measured by HAQ and quality of life measured by SF-36 (PCS and MCS) in RA patients who used therapy with biological agents compared to conventional therapy with DMARDq. Most of the systematic reviews presented high methodological quality evaluated by the AMSTAR tool and the quality of the evidence ranged from low to high quality by GRADE. The improvement in functional capacity and quality of life observed in the initial period of treatment (24 weeks) with biological therapy presented low clinical relevance. This difference between the treatments was not observed in the long term (52 weeks), mainly with the biological agents in the form of monotherapy. CONCLUSION: Evidence that varied between low to high quality demonstrated that biological agents presented improvement with low clinical relevance of the functional capacity and quality of life during the initial period of treatment compared to conventional therapy with DMARDq. However, there are no differences in the long term between the use of biological therapy and conventional therapy

This study focuses on the Pakistan National Alliance (PNA) and the movement associated with that party, in the aftermath of the 1977 elections in Pakistan. Through this study, the author addresses the issue of regionalism and its effects on politics at a National level. A study of the course of the movement also allows one to look at the problems in representation and how ideological stances merge with material conditions and needs of the country’s citizenry to articulate the desire for, what is basically, an equitable form of democracy that is peculiar to Pakistan. The form of such a democratic system of governance can be gauged through the frustrations and desires of the variety of Pakistan’s oppressed classes. Moreover, the fissures within the discourses that appear through the PNA, as well as their reassessment and analysis helps one formulate a fresh conception of resistance along different matrices of society within the country. / text

Class of 2012 Abstract / Specific Aims: To evaluate the presence of statistical information from clinical studies in official product labeling specific for disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of rheumatoid arthritis. Methods: Data were abstracted from official product labeling DMARDs with FDA approval for treatment of rheumatoid arthritis. Each document was examined for the presence of statement regarding a priori type 1 error rate, p-values, and measures of variance. Medications were classified as either biologic or non-biologic. Main Results: A total of 14 DMARDs, 7 biologics (50%) and 7 non-biologics (50%), were found to be FDA approved for the treatment of rheumatoid arthritis. Primary outcomes consisted of American College of Rheumatology (ACR) response rates, radiographic changes, and health assessment questionnaire score (HAQ). Any measure of variance and the presence of a p-value were both found in six (43%) of the drug labels. Inclusion of p-values was found to be significantly greater in biologics compared to non-biologics for both ACR and radiographic results. Inclusion of variance was found to be significantly greater in biologics compared to non-biologics for radiographic changes only. No package inserts contained statements regarding the a priori type I error rate. Conclusions: Measures of variance are not frequently included in product labeling for either biologic or non-biologic DMARDs. However, inclusion of variance and p-values for ACR response rates and radiographic changes were more likely to be reported for biologics therapies as compared to non-biologics. A statement regarding Type 1 error rates were absent from labels regardless of outcome assessed.

No description available.